Design and Characterization of a Parenteral Formulation of Meloxicam

DOI:

https://doi.org/10.37285/ijpsn.2010.3.1.7

Authors

  • Swamy P V
  • Neelima Tyagi
  • S.B. Shirsand
  • S A Raju

Abstract

Parenteral formulation of meloxicam was developed using pH 9.2 glycine-sodium hydroxide buffer containing 10% v/v of dimethylacetamide as the solvent. Various batches of meloxicam injection formulation were prepared in order to assess the influence of light, atmospheric oxygen and antioxidants (sodium bisulfite; sodium sulfite and thiourea) on the stability of the drug and the formulations were also subjected to accelerated stability testing (at 40o, 50o and 60o C) in order to predict the shelf-life of the product. Since light and atmospheric oxygen reduced the stability of the formulation, air in the ampoules was replaced with an inert gas (carbon dioxide) and the product was filled in amber coloured containers (ampoules). Sodium bisulfite (0.15% w/v) as an antioxidant gave a shelf-life of approximately 200 days under ambient temperature conditions.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Meloxicam, parenteral formulation, dimethylacetamide, glycine-sodium hydroxide buffer, shelf-life, sodium bisulfite, sodium sulfite, thiourea

Downloads

Published

2010-05-31

How to Cite

1.
P V S, Tyagi N, Shirsand S, Raju SA. Design and Characterization of a Parenteral Formulation of Meloxicam. Scopus Indexed [Internet]. 2010 May 31 [cited 2024 Jul. 6];3(1):844-52. Available from: http://ijpsnonline.com/index.php/ijpsn/article/view/475

Issue

Vol. 3 No. 1 (2010): April-June 2010

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413-20 (1995).

Insel PA. Analgesics-Antipyretic and Anti-inflammatory agents. In; The Pharmacological Basis of Therapeutics, Gilman A.G., Goodman L.S., Hardman J.G (eds)., 9th Edition, Volume II, McGraw Hill, New York, 1996, p.641.

Narjes H, Turck D, Busch U, Heinzel G, Nehmiz G. Pharmacokinetics and tolerability of meloxicam after intra-muscular administration. Br. J. Clin. Pharmacol. 41(2): 135-9 (1996).

Rawat S, and Jain S.K., A calorimetric method for determination of meloxicam in pharmaceutical dosage forms. Indian Drugs 41(2): 106 (2004).

Seedher N and Bhatia. Solubility enhancement of COX-2 inhibitors using various solvent systems. AAPSPharmSciTech. 4(3): Article 33 (2004).

Sol Motola and Shreeram Agharkar. Preformulation research of parenteral medication. In: Pharmaceutical Dosage forms: Parenteral medication, volume 1, Kenneth E. Avis, Leon Lachman and Herbert A Liebermann (eds.). Marcel Dekker Inc., New York, 1984, pp.105-107.

Stei P, Kruss B, Weigleb J and Trach V. Local tissue tolerability of meloxicam. Rheumatology 35: 45-50 (1996).

Sweetman SC (ed). Martindale: The Complete Drug Reference, 33rd edition, Pharmaceutical Press, London, 2002; pp.51-52.